208 related articles for article (PubMed ID: 15261431)
1. Pathology of malignant mesothelioma.
Van Marck E
Lung Cancer; 2004 Aug; 45 Suppl 1():S35-6. PubMed ID: 15261431
[TBL] [Abstract][Full Text] [Related]
2. Scoring system for differential diagnosis of malignant mesothelioma and reactive mesothelial cells on cytology specimens.
Kimura N; Dota K; Araya Y; Ishidate T; Ishizaka M
Diagn Cytopathol; 2009 Dec; 37(12):885-90. PubMed ID: 19572412
[TBL] [Abstract][Full Text] [Related]
3. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma.
Ylagan LR; Zhai J
Diagn Cytopathol; 2005 Mar; 32(3):137-44. PubMed ID: 15690333
[TBL] [Abstract][Full Text] [Related]
4. D2-40: a reliable marker in the diagnosis of pleural mesothelioma.
Müller AM; Franke FE; Müller KM
Pathobiology; 2006; 73(1):50-4. PubMed ID: 16785767
[TBL] [Abstract][Full Text] [Related]
5. The use of histological and immunohistochemical markers to distinguish pleural malignant mesothelioma and in situ mesothelioma from reactive mesothelial hyperplasia and reactive pleural fibrosis.
Cury PM; Butcher DN; Corrin B; Nicholson AG
J Pathol; 1999 Oct; 189(2):251-7. PubMed ID: 10547583
[TBL] [Abstract][Full Text] [Related]
6. Applications and limitations of immunohistochemistry in the diagnosis of malignant mesothelioma.
Suster S; Moran CA
Adv Anat Pathol; 2006 Nov; 13(6):316-29. PubMed ID: 17075297
[TBL] [Abstract][Full Text] [Related]
7. Parathyroid hormone-related protein antigen localization distinguishes between mesothelioma and adenocarcinoma of the lung.
Clark SP; Chou ST; Martin TJ; Danks JA
J Pathol; 1995 Jun; 176(2):161-5. PubMed ID: 7636626
[TBL] [Abstract][Full Text] [Related]
8. Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.
Mimura T; Ito A; Sakuma T; Ohbayashi C; Yoshimura M; Tsubota N; Okita Y; Okada M
Cancer; 2007 Mar; 109(5):933-8. PubMed ID: 17279584
[TBL] [Abstract][Full Text] [Related]
9. Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?
Deniz H; Kibar Y; Güldür ME; Bakir K
Pathol Res Pract; 2009; 205(11):749-52. PubMed ID: 19573998
[TBL] [Abstract][Full Text] [Related]
10. Manganese superoxide dismutase as a diagnostic marker for malignant pleural mesothelioma.
Kahlos K; Pääkkö P; Kurttila E; Soini Y; Kinnula VL
Br J Cancer; 2000 Mar; 82(5):1022-9. PubMed ID: 10737384
[TBL] [Abstract][Full Text] [Related]
11. Differentiation of mesothelioma from adenocarcinoma in serous effusions: the role of hyaluronic acid and CD44 localization.
Afify AM; Stern R; Michael CW
Diagn Cytopathol; 2005 Mar; 32(3):145-50. PubMed ID: 15690337
[TBL] [Abstract][Full Text] [Related]
12. Pathology of diffuse malignant pleural mesothelioma.
Corson JM
Semin Thorac Cardiovasc Surg; 1997 Oct; 9(4):347-55. PubMed ID: 9352951
[TBL] [Abstract][Full Text] [Related]
13. The distinction of mesothelioma from adenocarcinoma in malignant effusions by electron microscopy.
Kobzik L; Antman KH; Warhol MJ
Acta Cytol; 1985; 29(3):219-25. PubMed ID: 3859121
[TBL] [Abstract][Full Text] [Related]
14. The role of immunohistochemistry in the diagnosis of malignant mesothelioma.
Moran CA; Wick MR; Suster S
Semin Diagn Pathol; 2000 Aug; 17(3):178-83. PubMed ID: 10968703
[TBL] [Abstract][Full Text] [Related]
15. Cytopathologic differential diagnosis of malignant mesothelioma, adenocarcinoma and reactive mesothelial cells: A logistic regression analysis.
Cakir E; Demirag F; Aydin M; Unsal E
Diagn Cytopathol; 2009 Jan; 37(1):4-10. PubMed ID: 18973123
[TBL] [Abstract][Full Text] [Related]
16. The differential diagnosis of epithelial-type mesothelioma from adenocarcinoma and reactive mesothelial proliferation.
Soosay GN; Griffiths M; Papadaki L; Happerfield L; Bobrow L
J Pathol; 1991 Apr; 163(4):299-305. PubMed ID: 2033489
[TBL] [Abstract][Full Text] [Related]
17. Proteoglycans and WT1 as markers for distinguishing adenocarcinoma, epithelioid mesothelioma, and benign mesothelium.
Gulyás M; Hjerpe A
J Pathol; 2003 Apr; 199(4):479-87. PubMed ID: 12635139
[TBL] [Abstract][Full Text] [Related]
18. Challenges and controversies in the diagnosis of mesothelioma: Part 1. Cytology-only diagnosis, biopsies, immunohistochemistry, discrimination between mesothelioma and reactive mesothelial hyperplasia, and biomarkers.
Henderson DW; Reid G; Kao SC; van Zandwijk N; Klebe S
J Clin Pathol; 2013 Oct; 66(10):847-53. PubMed ID: 23814259
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic utility of calretinin immunohistochemistry in cytologic cell block preparations.
Wieczorek TJ; Krane JF
Cancer; 2000 Oct; 90(5):312-9. PubMed ID: 11038429
[TBL] [Abstract][Full Text] [Related]
20. Image cytometry: an aid for cytological diagnosis of pleural effusions.
Osterheld MC; Liette C; Anca M
Diagn Cytopathol; 2005 Mar; 32(3):173-6. PubMed ID: 15690335
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
